{"id":"brivanib-800-mg-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL270995","moleculeType":"Small molecule","molecularWeight":"441.46"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Brivanib inhibits both FGFR and VEGFR signaling pathways, which are critical for tumor angiogenesis and growth. By blocking these receptor tyrosine kinases, the drug reduces new blood vessel formation to tumors and directly inhibits cancer cell proliferation. This dual-target approach aims to overcome resistance mechanisms that may develop with single-pathway inhibition.","oneSentence":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:02:37.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT04212221","phase":"PHASE1, PHASE2","title":"MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients","status":"TERMINATED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2020-04-20","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":89},{"nctId":"NCT00640471","phase":"PHASE3","title":"Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2008-05-12","conditions":"Colorectal Cancer","enrollment":750},{"nctId":"NCT03516071","phase":"PHASE2","title":"A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2017-05-17","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT00594984","phase":"PHASE1, PHASE2","title":"Phase I/II Combination With Irinotecan- Erbitux","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-05","conditions":"Metastatic Colorectal Cancer (MCRC)","enrollment":38},{"nctId":"NCT00437437","phase":"PHASE1","title":"A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-05","conditions":"Tumors","enrollment":29},{"nctId":"NCT00207051","phase":"PHASE1","title":"BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-01","conditions":"Colorectal Cancer","enrollment":62},{"nctId":"NCT00435669","phase":"PHASE1","title":"A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-09","conditions":"Tumors","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Brivanib 800 mg, QD","genericName":"Brivanib 800 mg, QD","companyName":"Zai Lab (Shanghai) Co., Ltd.","companyId":"zai-lab-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation. Used for Hepatocellular carcinoma, Advanced solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}